Short Bowel Syndrome clinical trials at UCSF
1 research study open to eligible people
open to all eligible people
This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.
San Francisco, California and other locations
Our lead scientists for Short Bowel Syndrome research studies include Sue Rhee, MD.